A $1.50 IPR&D Charge Makes a Strong Quarter Look Like a Collapse — But the Real Story Is a 21% Run-Up Meeting a Full Price. Maintaining Hold.

Results vs. Consensus

Q3 2025 Scorecard

Year-Over-Year Comparison

Sequential (QoQ) Context

The sequential adjusted-EPS line (−37.4%) is pure IPR&D noise — Q2 carried a $0.42 charge, Q3 carried $1.50. On an ex-IPR&D basis the two quarters earned roughly $3.39 and $3.36 respectively — essentially flat, exactly as you would expect from a business growing revenue 2.3% sequentially with stable margins. The aesthetics sequential dip is partly seasonal (Q3 is a softer aesthetics quarter), so read the YoY deceleration (−3.7% vs. −8.1% in Q2), not the QoQ, for the trend.

Quality of Beat

Revenue: The ~$300M revenue overachievement was concentrated where the thesis wants it — Skyrizi and Rinvoq in immunology and a broad-based neuroscience beat — not in one-time items or stocking. Reported growth of 9.1% versus operational growth of 8.4% means foreign exchange was a modest favorable tailwind; this was an organic-demand beat. The number that matters most is again off the scorecard: the ex-Humira platform grew more than 20%, and Humira finally fell below $1B for the first time, so the drag from the cliff is now a small and shrinking line.

Margins: The reported adjusted operating margin of 30.9% looks alarming against the high-40s the franchise normally prints, but it carries a 17-point unfavorable hit from acquired IPR&D this quarter. Strip it and the underlying operating margin is back in the high-40s, consistent with AbbVie at scale; the CFO reaffirmed a full-year adjusted operating margin of ~41% (which itself absorbs ~6 points of YTD IPR&D). Adjusted gross margin of 83.9% was in line. The mix is still quietly improving: the highest-margin franchises (immunology, neuroscience) are growing fastest while the lowest-incremental-margin one (aesthetics) shrinks more slowly than before.

EPS: The GAAP-to-adjusted gap is at its widest of the year — $0.10 GAAP versus $1.86 adjusted — almost entirely attributable to amortization of acquired intangibles (the Allergan/Cerevel/ImmunoGen legacy) plus the $1.50 IPR&D charge run through the adjusted line and its lower tax deductibility (which pushed the adjusted tax rate to 24.5% from the usual mid-teens). The 38.0% adjusted-EPS decline looks like a profit collapse in isolation but is a function of one quarter's BD timing, not deteriorating economics. Ex-IPR&D the operational earnings grew ~12% YoY — the cleanest read of the underlying quarter.

Segment Performance

Therapeutic-Area Revenue Mix — Q3 2025

Immunology — The Engine Compounds, and the Cliff Finally Becomes a Footnote

Immunology delivered $7.885B (+11.9% reported, +11.2% operational), but the composition is the story. Skyrizi grew 46% operationally to $4.708B and Rinvoq grew 34.1% operationally to $2.184B — a combined ~$6.9B growing more than 40% — while Humira fell 55.7% operationally to $993M, its first quarter below the $1B mark. The crossover is now decisive and largely behind the company: the two growth assets are adding roughly $2B+ of YoY revenue while Humira sheds a shrinking absolute amount. Management again emphasized that gastroenterology is the marginal driver, with Skyrizi and Rinvoq together capturing roughly half of newer switching Crohn's patients and nearly one in three switching ulcerative-colitis patients in the U.S.

"I'm especially pleased with our portfolio performance in gastroenterology, where these 2 medicines are on pace to nearly double their combined sales in IBD this year." — Jeff Stewart, Chief Commercial Officer

The durability question got another confident answer. Management argued the IL-23 class is still early in IBD — NBRx share in ulcerative colitis has moved from ~5% to nearly 40% in a little over a year — and stressed that the recently expanded Rinvoq IBD label (allowing use before anti-TNFs in certain patients) is a "net incremental positive" that will build over time. Crucially, management framed the TREMFYA competitive threat as class expansion rather than share loss: "this is not a zero-sum game."

Assessment: This is the load-bearing wall of the thesis and it is intact and, if anything, stronger than at Q2. Humira dropping below $1B is a milestone — the cliff that defined the bear case for five years is now a sub-$1B, fast-fading line item, and the lost volume continues to convert upward into Skyrizi/Rinvoq rather than leaking entirely to biosimilars. The only debate left on this franchise is the multiple you pay for it, not the trajectory.

Neuroscience — The Second Engine Keeps Compounding

Neuroscience grew 20.2% reported (19.6% operational) to $2.841B, with the migraine portfolio (Ubrelvy + Qulipta combined $642M, Botox Therapeutic $985M) and psychiatry (Vraylar $934M, +6.7%) all contributing. Qulipta is now the #1 CGRP treatment for migraine prevention at ~7.5% total prescription share. The standout remains Parkinson's: Vyalev grew 40% sequentially to $138M, with management calling international uptake "transformative" and now actively expanding the U.S. field force ahead of an expected coverage inflection and the pending tavapadon approval.

"VYALEV's launch trajectory has been very impressive. Total sales were $138 million, up 40% on a sequential basis... we are now actively expanding our field sales team to support higher anticipated demand next year." — Jeff Stewart, Chief Commercial Officer

Management used the call to argue, again, that the Street under-weights neuroscience — "our second largest therapeutic area and the fastest growing in our portfolio" — pointing to leadership positions in psychiatry and migraine and an emerging multi-asset Parkinson's franchise (Vyalev + tavapadon + Duopa) on top of optionality from the Aliada Alzheimer's platform and the new Gilgamesh/Gedeon Richter mood-disorder assets.

Assessment: Neuroscience remains the most underappreciated part of the story and a genuine second pillar. At 18% of revenue and growing ~20%, it is increasingly the swing factor in whether AbbVie compounds high-single or low-double-digits through the decade. The Vyalev/tavapadon Parkinson's leg is the cleanest piece of un-modeled optionality in the portfolio. As at Q2, the flat-to-down stock reaction did not reward it.

Oncology — The Drag Narrows to Roughly Flat

Oncology was essentially flat at $1.682B (−0.3% reported, −1.3% operational) — an improvement from a portfolio that has been the persistent laggard. Venclexta ($726M) edged ahead of Imbruvica ($706M) for the first time as the lead oncology asset, with Elahere ($170M), Epkinly and EMRELIS helping offset Imbruvica's continued CLL erosion. The revenue line is less compelling than the R&D narrative: at ESMO, management presented three orals for the Temab-A ADC (including a 30% ORR in late-line colorectal cancer versus 0% for standard of care and a 47% ORR in MET-amplified solid tumors), and a Phase III CRC program is planned.

"Momentum from Venclexta as well as newer products, Elahere, Epkinly and EMRELIS helped to offset the expected sales decline from Imbruvica, which continues to be impacted by competitive dynamics in CLL." — Jeff Stewart, Chief Commercial Officer

Assessment: Oncology is no longer dragging the consolidated growth rate the way it did — flat is a step up from the low-single-digit growth of prior quarters, and the Venclexta-over-Imbruvica crossover means the declining asset is now a smaller share of the mix. But the segment still has the least to show today for its ambitions; the next-gen ADC and trispecific assets are mostly 2027+ stories. Net: neutral for the near-term model, an option on the back half of the decade.

Aesthetics — The Decline Moderates, but Growth Has Not Returned

Aesthetics fell 3.7% reported (4.2% operational) to $1.193B, with Botox Cosmetic at $637M and Juvederm at $253M both declining. The headline matters: this is a clear deceleration of the decline from the −8.1% reported in Q2. Management still frames the category, not AbbVie's position, as the problem — consumer sentiment "remaining quite low, especially in the U.S." — and continues to defend share (Botox in the low-60s% of the U.S. toxin market, HA fillers ~45%) rather than market growth.

"While our portfolio is performing well from a competitive perspective, we continue to face challenging market conditions in several key markets... we now see category growth tracking below our previous assumptions globally." — Jeff Stewart, Chief Commercial Officer

Management lowered the FY25 aesthetics guide a further $200M to ~$4.9B, citing "greater-than-expected market softness globally," even as the year-over-year rate of decline improved. The defense rests on consumer campaigns now in market (showing "some nice pickup"), a stabilizing — if not recovering — filler sentiment, and the 2026 TrenibotE launch (a fast-acting, short-duration toxin) as the category catalyst.

Assessment: This is the most important incremental change in the quarter for the bear pillar. The decline moderating to −3.7% from −8.1% is the first evidence in several quarters that aesthetics may be approaching a trough — but management cut the full-year aesthetics number again, so a confirmed trough is not yet in hand. We read it as "less bad, not yet good." It moves aesthetics from a clear drag toward a stabilizing line, which is supportive, but it is not yet the "confirmed aesthetics trough" that is one of our explicit upgrade triggers.

Key Topics & Management Commentary

Overall Management Tone: The call was confident and well-rehearsed, leaning forward on the immunology and neuroscience engines and on a relentless business-development cadence (30+ deals since the start of last year), with the third FY25 raise delivered as a matter of routine. The posture was most assured on the growth platform and notably less defensive on aesthetics than at Q2 — the "more chronic" concession of last quarter softened into "category below our assumptions, but our share is holding and we're investing through it." Management spent unusual airtime pre-empting the IPR&D optics, framing the charge as the expected cost of building the 2030s pipeline rather than anything to apologize for.

1. The IPR&D Charge: A $1.50 Bill for Building the Next Decade

The defining number of the quarter is the $1.50-per-share charge for acquired IPR&D and milestones, primarily the upfront cost of the Capstan Therapeutics acquisition (in vivo CAR-T for immunology) and the IGI license. Because AbbVie runs IPR&D through adjusted EPS, the charge converted what was operationally a ~$3.36 quarter into a reported $1.86, and dragged the FY25 guide and the operating-margin and tax-rate ratios with it. Management treated it as routine.

"These results include a $1.50 unfavorable impact from acquired IPR&D expense, primarily reflecting upfront charges for the acquisition of Capstan Therapeutics and our license agreement with IGI." — Scott Reents, Chief Financial Officer

The CFO was explicit that the new FY25 EPS guide of $10.61–$10.65 "does not include an estimate for acquired IPR&D expense that may be incurred beyond the third quarter," and that the YTD IPR&D drag is now $2.05/share. So the headline guide moved up $0.03–$0.07 versus the prior $10.38–$10.58 range, but only because the operational raise more than offset the accumulating charge.

Assessment: This is the analytical centerpiece of the quarter, and getting it right is the difference between "AbbVie's profit collapsed 38%" and "AbbVie beat and raised while spending aggressively on its pipeline." It is the latter. The cost of the BD machine is a perpetually noisy adjusted line and a guide that will be mechanically reduced by each new deal — a feature, not a surprise. For investors who can look through it, the operating quarter beat; for those who anchor on the reported headline, it reads as a miss. The market, on the day, anchored on the headline.

2. The Third FY25 Raise — Operational Lift Masked by IPR&D Math

Management raised FY25 for the third time this year, lifting the adjusted-EPS range to $10.61–$10.65 and the total revenue outlook by ~$400M. Underneath the headline, the revenue mix shifted: Skyrizi raised $200M to $17.3B, neuroscience raised $200M to $10.7B, and aesthetics cut $200M to $4.9B — a textbook "raise the structural franchises, trim the consumer one" reshaping.

"Given our positive momentum, we are raising our 2025 outlook for the third time this year... We've now beaten and raised it every quarter of '25." — Rob Michael, Chairman & CEO

Assessment: A third consecutive beat-and-raise is unambiguously good and demonstrates the durability of the growth platform. But the headline EPS raise is small ($0.03–$0.07 at the edges) and obscured by IPR&D, which is precisely the kind of "good but it looks complicated" update that a stock already up 21% on the year struggles to rally on. The operational raise is real; the optics are not flattering.

3. The 5.5% Dividend Increase — The Capital-Allocation Signal

AbbVie announced a 5.5% increase in the quarterly dividend to $1.73 per share, beginning with the February 2026 payment — the company's continuation of an uninterrupted record of annual raises (the quarterly dividend is up more than 330% since the 2013 inception). The CFO tied it to ~$13B of free cash flow generated in the first nine months (including ~$2.2B of Skyrizi royalty payments) and reaffirmed the path to a 2x net-leverage ratio by end-2026.

"This free cash flow fully supports strong and growing quarterly dividend, which we are increasing 5.5% to $1.73 per share, beginning with the dividend payable in February 2026." — Scott Reents, Chief Financial Officer

Assessment: The raise is a clear statement of management's confidence in the durability of cash flow through the Humira tail and the IPR&D-heavy BD cadence — you do not raise the dividend 5.5% if you are worried about funding the deal machine. At the $218 reaction-day close the indicated forward yield is ~3.2%, which provides a meaningful floor to the total-return math and is part of why the stock is a Hold rather than an Underperform even after a 21% run. It is a positive, but a modest one — the raise is in line with the recent cadence, not an acceleration.

4. Humira Below $1B — The Cliff Becomes a Tail

Humira fell 55.7% operationally to $993M — the first quarter below the $1B threshold — with management guiding continued U.S. access erosion into 2026 as more plans adopt exclusionary contracts, partially offset by a price benefit from those same contract changes. The CFO noted the U.S. Humira step-down is "just over $4 billion" this year, with the absolute decline diminishing thereafter.

"Turning now to Humira, which delivered global sales of $993 million, down 55.7% on an operational basis, reflecting biosimilar competition." — Jeff Stewart, Chief Commercial Officer

Assessment: A symbolic and substantive milestone. Sub-$1B means Humira is now ~6% of revenue and shrinking — small enough that even continued percentage erosion produces a manageable absolute drag, and the company is growing comfortably through it. The bear's original five-year cliff narrative is effectively closed; the residual debate is the deceleration math on the growth drugs, not the legacy asset.

5. Skyrizi + Rinvoq and the Deferred Long-Term Guide Raise

The single most important commercial fact is that Skyrizi (+46% op.) and Rinvoq (+34% op.) are now compounding a combined >$6.9B quarterly run-rate, and management all but confirmed it will exceed its 2027 long-term targets — while again declining to formally refresh that guidance until the Q4 call. Management noted the combined 2025 raise is now ~$1.7B above the figure used to set the last long-term guide.

"Since then, we have raised the combined guidance for 2025 by over $1.7 billion. So it's reasonable to assume that we will exceed that long-term guidance. And I think that will be very clear when we provide 2026 guidance on the upcoming Q4 call." — Rob Michael, Chairman & CEO

Assessment: This is the same dynamic that produced the Q2 fade: the numbers are demonstrably conservative, the Street knows it, and management is holding the formal refresh for Q4/JPM. The strategy is disciplined and the trajectory is excellent, but deferring the most obvious re-rating catalyst leaves a stock that has already run with no fresh fuel on the day. A formal long-term-guide raise remains one of our explicit upgrade triggers — and it was, once again, deferred.

6. Aesthetics: Less Bad, but the Guide Got Cut Again

The aesthetics tone was notably less defensive than the "more chronic" concession of Q2: management pointed to consumer campaigns in market with "some nice pickup," a filler-sentiment metric that has "stabilized to some degree," and the 2026 TrenibotE launch as a catalyst. Yet it simultaneously cut the FY25 aesthetics revenue guide a further $200M to ~$4.9B on "greater-than-expected market softness globally."

"With overall consumer sentiment remaining quite low, especially in the U.S... we now see category growth tracking below our previous assumptions globally. However, this near-term macro pressure does not dampen our excitement for the long-term potential." — Jeff Stewart, Chief Commercial Officer

Assessment: The two signals point in opposite directions — the YoY decline is moderating (−3.7% vs. −8.1%), which is the trough-forming pattern, but the full-year guide cut says the absolute level is still being marked down. The honest read is "stabilizing, not recovered." This is genuinely better than Q2 and supports the case that aesthetics caps rather than breaks the thesis; it is not yet the confirmed trough that would justify upgrading.

7. Business Development: 30+ Deals, the Pipeline Bet for the 2030s

Management again framed capital allocation around building the next decade rather than plugging a near-term hole: ~30 deals since the start of 2024, with recent additions including Capstan (in vivo CAR-T), Gilgamesh's bretisilocin (a next-gen psychedelic for MDD), and license deals in obesity (amylin) and oncology (trispecifics). The $1.50 IPR&D charge is the visible cost. Management also reiterated a $10B+ U.S. capital commitment over ten years (a new API site in North Chicago, biologics expansion in Worcester).

"Our BD focus continues to be on assets that can drive growth in the next decade and beyond... we certainly have the financial wherewithal to pursue late-stage opportunities as well. But that's not really a need given that our current portfolio provides a clear line of sight to growth into the next decade." — Rob Michael, Chairman & CEO

Assessment: The BD machine remains a genuine differentiator — with no major LOE this decade, AbbVie funds pipeline optionality out of cash flow rather than diluting or over-levering. The cost is the recurring, lumpy IPR&D drag that distorts every adjusted print (as this quarter showed in extreme form). For a Hold thesis this is a wash: long-duration value creation paid for with near-term reported-EPS noise.

8. Pipeline Catalysts: Alopecia, Vitiligo, Parkinson's, and an Obesity Option

R&D leadership flagged a dense slate of near-term readouts: positive Phase III Rinvoq data in both alopecia areata and vitiligo (with regulatory submissions planned for late 2025 / early 2026), the tavapadon Parkinson's submission to the FDA, the PVEK oncology submission, and a 2026 wave of IBD combination data (lutikizumab + Skyrizi), Temab-A readouts in new tumors, and early obesity (amylin) data. Management sized the "next wave" of Rinvoq dermatology indications (alopecia, vitiligo, HS, lupus) at $2B+ in peak sales.

"When you look at... the next big 4 — alopecia areata, vitiligo, HS, and then lupus — we've looked and sized those that revenue potential is at least $2 billion at peak." — Jeff Stewart, Chief Commercial Officer

Assessment: These extend the immunology and neuroscience runways into the late 2020s and reinforce that the franchise has multi-year duration beyond the current indication set. Positive for the long-term thesis, but largely 2027–2029 contributors — they support the durability case without changing the near-term setup that drives a Hold today.

9. Policy: PBM Reform, IRA, and Tariffs — Adaptable, Insulated, Deferred

On the newly floated Cigna PBM model and broader PBM reform, management's posture was that AbbVie's performance is driven by differentiated medicines and execution — "we deliver similar strong performance in markets outside the U.S. where PBMs and DTC do not play a role" — and that it can adapt to any structure. On IRA, the Vraylar/Linzess negotiated prices (effective 2027, not 2026) "will not impact our long-term guidance." On tariffs, management reiterated active engagement with the administration and a willingness to expand direct-to-patient models, while pricing Elahere in the U.K. at the U.S. list price as a most-favored-nation gesture.

"Ultimately, what drives AbbVie's performance is our differentiated medicines, along with our execution track record and strong culture... If there are changes to the PBM model, we will certainly be able to adapt effectively." — Rob Michael, Chairman & CEO

Assessment: Adequately handled and not a 2025 or 2026 P&L issue on management's telling. The policy overhang (PBM reform, IRA Round 2, Section 232 tariffs) remains a latent, unquantified risk for 2027+ rather than an active thesis driver, and management's "we adapt to any structure" framing is credible given the ex-U.S. track record — but it is a holding statement, not a quantification.

Guidance & Outlook

The crucial framing point: the FY25 adjusted-EPS guide moved up at the edges (to $10.61–$10.65 from $10.38–$10.58), but only because a genuine operational lift more than absorbed the accumulating IPR&D drag (now $2.05/share YTD). On an operational, ex-IPR&D basis the underlying earnings power is higher than the headline implies — the Q4 guide of $3.32–$3.36 (which excludes any future IPR&D) is the clean number, and it points to a strong finish. The revenue mix raise — Skyrizi +$200M, neuroscience +$200M, aesthetics −$200M — is the structural franchises doing exactly what the thesis expects while the consumer-cyclical one is trimmed again.

Implied Q4 ramp: The Q4 revenue guide of >$16.3B (with a ~1% FX tailwind) implies continued mid-to-high-single-digit operational growth and a modest sequential step-up from Q3's $15.776B — consistent with the Skyrizi/Rinvoq/neuroscience momentum net of the Humira step-down. The Q4 adjusted-EPS guide of $3.32–$3.36 (ex-IPR&D) is up from the ~$3.36 ex-IPR&D earned in Q3, i.e., roughly flat-to-up sequentially on the clean basis.

Street at: Pre-print, the Street carried ~$12 FY25 (ex-IPR&D framing) and ~$14.42 FY26. The reported IPR&D-inclusive FY25 guide of $10.61–$10.65 sits below that because of the basis difference, not a downgrade — reconciling the two requires adding back the $2.05 YTD IPR&D, which lands the operational figure back near the Street's ex-IPR&D number.

Guidance style: Characteristically conservative. AbbVie has now beaten and raised every quarter of 2025 and still declined to refresh long-term Skyrizi/Rinvoq targets despite repeated prompting, preferring the Q4/JPM update. For a name priced for execution, this measured cadence is prudent but offers the stock little fresh near-term fuel — the same setup that produced the Q2 fade.

Analyst Q&A Highlights

The 2026 Setup and What the Street May Be Mis-Modeling

A recurring line of questioning sought an early read on 2026 — the pushes and pulls into next year and anything the Street is getting wrong. Management declined to give specifics ahead of the Q4 guide but argued the breadth of overperformance (not just Skyrizi/Rinvoq, but neuroscience and oncology ahead of original plan) should support strong 2026 growth despite continued Humira erosion and the Imbruvica IRA price taking effect.

Q: "Any initial look on 2026 as you think about the various pushes and pulls in the business? And anything in particular you think the Street isn't properly accounting for as we think about the outlook for next year?"
— Chris Schott, JPMorgan

A: "We've raised our revenue forecast this year by nearly $2 billion since our initial guidance in February, and that's not just coming from Skyrizi and Rinvoq. We're seeing overperformance across the entire neuroscience portfolio and oncology is ahead of our original guidance as well. That momentum should allow us to deliver strong growth next year despite headwinds from continued Humira erosion and Imbruvica IRA pricing... we'll provide specific guidance for '26 on the fourth quarter call."
— Rob Michael, Chairman & CEO

Assessment: A confident, content-light answer — management telegraphed strong 2026 growth and named the two known headwinds (Humira tail, Imbruvica IRA price effective 2026) without quantifying. The breadth point is the substantive tell: the raise is no longer a two-drug story, which de-risks the 2026 growth bridge. But the absence of numbers, again, leaves the obvious catalyst for Q4.

Whether the 2027 Skyrizi/Rinvoq Targets Will Be Formally Raised

Questioning pressed directly on updating the long-term Skyrizi/Rinvoq outlook given both are tracking well above the 2027 targets. Management again declined to refresh now, all but confirming the targets will be exceeded and deferring the formal update to the Q4 call — while arguing the more important point is the depth of the pipeline beyond the two flagship drugs.

Q: "I'm curious your thoughts around updating the Street on sort of your longer-term outlook for Skyrizi and Rinvoq."
— Vamil Divan, Guggenheim Securities

A: "Since then, we have raised the combined guidance for 2025 by over $1.7 billion. So it's reasonable to assume that we will exceed that long-term guidance. And I think that will be very clear when we provide 2026 guidance on the upcoming Q4 call... to me, it's more important that investors appreciate the depth of our pipeline that can drive growth in the next decade versus updating financial guidance again for this decade."
— Rob Michael, Chairman & CEO

Assessment: A confident non-answer, identical in structure to Q2. Management is clearly tracking well ahead of the >$20B/>$11B targets but is holding the upgrade for Q4/JPM. This is the crux of the fade: the Street already knows the numbers are conservative, so deferring the refresh leaves no near-term re-rating catalyst even as the trajectory strengthens. The pivot to "appreciate the pipeline depth" is a tell that the next leg of the story management wants credit for is the 2030s pipeline, not another near-term guide bump.

Aesthetics: What the Leading Indicators of a Rebound Are

Questioning probed for "green shoots" in aesthetics given the protracted weakness and the commercial/DTC investments. Management acknowledged the conditions have been "more protracted than we anticipated" but pointed to consumer-confidence, middle-income toxin demand, and a monthly HA-filler sentiment metric (now stabilizing) as the leading indicators it watches, with TrenibotE the 2026 catalyst.

Q: "It still seems that we're seeing more macro headwinds [in aesthetics]... what would you say are the leading indicators of a rebound? I'm just trying to assess what green shoots perhaps you may be seeing."
— Geoff Meacham, Citibank

A: "These market conditions have been more protracted than we anticipated. So it's challenging to predict... we're looking at sort of overall consumer confidence. It's quite low... we're monitoring every month sort of the HA filler sentiment. So we've seen that stabilize to some degree, which is good. It's not continuing to go down."
— Jeff Stewart, Chief Commercial Officer

Assessment: More candid and slightly more constructive than Q2's "more chronic." The "stabilizing, not continuing to go down" framing on filler sentiment, paired with the moderating −3.7% revenue decline, is the first tentative evidence of a bottoming process. But "challenging to predict" and another guide cut mean management still will not call a trough — consistent with our "less bad, not yet good" read.

The Parkinson's Franchise: Vyalev Competitive Position and Tavapadon

A detailed exchange probed Vyalev's uptake against the competing 16-hour subcutaneous therapy and tavapadon's positioning against genericized oral options. Management laid out an unusually granular competitive case for Vyalev (24-hour vs. 16-hour coverage, ~80–85% in-play capture, lower dyskinesia/sedation rates) and framed tavapadon as a complementary once-daily oral that approaches levodopa efficacy with a differentiated safety profile.

Q: "I wanted to drill down on your Parkinson's franchise. Can you talk to uptake of VYALEV and specifically what you're seeing regarding competitive dynamics... And then on tavapadon... how are you thinking about sales potential there?"
— David Amsellem, Piper Sandler

A: "The in-play capture right now is roughly 80%, 85% in favor of VYALEV. And that's because of the 24-hour coverage, you have far less supplemental orals... in some cases, we've launched VYALEV after subcu apomorphine has been available in the international countries. And essentially, the shares invert very, very rapidly."
— Jeff Stewart, Chief Commercial Officer

Assessment: This is the clearest articulation yet of the Parkinson's leg the market under-models. An 80–85% in-play capture rate with share-inversion against an incumbent is a strong competitive signal, and tavapadon adds an oral complement ahead of launch. The franchise (Vyalev + tavapadon + Duopa) is the cleanest piece of neuroscience optionality — additive to the thesis, not yet in most models.

Accelerating Growth as the Humira Decline Diminishes

Questioning sought the shape of the growth curve as Humira's absolute-dollar declines shrink. The CFO confirmed the Humira step-down (~$4B U.S. this year) will diminish in absolute terms next year, reaffirmed the high-single-digit revenue CAGR through the decade, and committed to bottom-line growing faster than the top line on SG&A leverage.

Q: "Could you please discuss the outlook for accelerating growth as Humira's absolute dollar declines diminish in coming years?"
— David Risinger, Leerink Partners

A: "Certainly, that step down in absolute dollars will diminish and will diminish next year as well... we still remain extremely confident in our ability to achieve that high single-digit growth through the decade on the top line. The bottom line will continue to expand... you will see earnings growth expand a little bit faster than the revenue growth through the decade."
— Scott Reents, Chief Financial Officer

Assessment: The most thesis-relevant answer on the call. As the Humira drag shrinks, the consolidated growth rate should converge toward the much higher ex-Humira platform rate (>20%), and operating leverage layers EPS growth on top. This is the mechanical case for AbbVie compounding through the decade — and it is why the business thesis is a clear Confirmed even as the stock stays a Hold on valuation.

M&A Strategy and Appetite for Larger Deals

The closing question probed BD priorities after Capstan and Gilgamesh, and whether AbbVie has appetite for larger transactions. Management reaffirmed the focus on novel mechanisms and platforms for the 2030s, said it has the wherewithal for late-stage deals but no need given the de-risked decade, and emphasized breadth across all five growth areas.

Q: "Any updated thoughts following the recent acquisitions, Capstan and Gilgamesh... And then just also curious if you have any appetite for larger deals?"
— Asad Haider, Goldman Sachs

A: "Our BD focus continues to be on assets that can drive growth in the next decade and beyond. I mean we certainly have the financial wherewithal to pursue late-stage opportunities as well. But that's not really a need given that our current portfolio provides a clear line of sight to growth into the next decade."
— Rob Michael, Chairman & CEO

Assessment: Management kept the door open to larger deals while reaffirming the early/mid-stage, platform-focused approach — consistent with the "build the next decade" framing. The reassurance that a big late-stage deal is "not a need" is meaningful for capital-allocation risk: it argues against a value-destroying mega-merger to plug a hole that does not exist. The flip side is that the recurring IPR&D drag (this quarter's $1.50) is now a structural feature of every print.

What They're NOT Saying

1. No refreshed long-term Skyrizi/Rinvoq guidance: For the second straight quarter, with both assets tracking well above the >$20B/>$11B 2027 targets and direct prompting, management held the upgrade for the Q4 call. The numbers are clearly conservative — but withholding the refresh removes the single most obvious near-term re-rating catalyst, which is again part of why the stock faded.
2. No 2026 numbers, only direction: Management telegraphed "strong growth" in 2026 and named the headwinds (Humira tail, Imbruvica IRA price) but quantified nothing. The absence of any framing range, on a stock that just ran 21%, is itself a signal that the de-risking event investors want is being saved for December.
3. No steady-state IPR&D run-rate: With ~30 deals since 2024 and a $1.50 charge this quarter ($2.05 YTD), management still does not give investors a way to model the normalized annual IPR&D that the adjusted number absorbs — the very line that turned a strong quarter into an ugly headline. Quantifying a "typical year" of IPR&D would de-mystify the adjusted EPS the stock is valued on; its absence keeps the print structurally noisy.
4. No date for an aesthetics trough: The decline moderated to −3.7%, but management cut the FY aesthetics guide again and would not put a date on a return to growth, retreating to share stability and the 2026 TrenibotE catalyst. "Stabilizing to some degree" is not "we expect growth in [period]."
5. No floor on Imbruvica: The asset is now below Venclexta and still eroding on CLL competition, but management offered no stabilization path or terminal-value framing for a still-$700M/quarter franchise that the IRA price will pressure further in 2026.
6. Quiet on the GAAP line: A $0.10 GAAP EPS against $1.86 adjusted is the widest gap of the year, and management addressed the IPR&D piece but not the full amortization-driven bridge or how investors should think about the cash-vs-accounting divergence over the BD-heavy next few years.

Market Reaction

• Pre-print setup: ABBV closed at $228.20 on October 30, entering the print up +28.4% YTD (from $177.70 at 2024 year-end) and +11.9% on a trailing-12-month basis — though down 6.6% over the trailing 30 days from an October 1 close of $244.38, near the top of its $164.99–$244.38 52-week closing range. Critically, the stock had run roughly +21% from the ~$189 level it closed at after the Q2 print in early August. The S&P 500 entered the day +16.0% YTD, so ABBV was a clear market leader heading in — the setup of a stock that had already rewarded the bulls.
• Reaction-day move (BMO print, same session): ABBV gapped down to open $223.00 (−2.3%), traded an intraday range of $216.00–$223.87, and closed at $218.04, −4.5% (−$10.16). Volume of 10.8M ran 1.8x the 6.0M 30-day average. The S&P 500 closed +0.3% on the day, so ABBV underperformed the market by roughly 4.8 points — a clear, decisive single-stock sell-off, not a tape effect.

The price action is the most important non-fundamental data point in this report, and it is the cleanest possible validation of the Hold thesis. A quarter where revenue beat, the platform compounded 40%+, the FY guide was raised, and the dividend was lifted 5.5% — sold off 4.5% on 1.8x volume. The proximate cause is the collision of two things: an ugly-optics IPR&D headline (a −38% adjusted-EPS print and a GAAP operating margin that compressed to ~12% from ~26% a year ago) that screens as a profit collapse to anyone not adjusting for the $1.50 charge, and a full price after a 21% run that left no room for a complicated "good but you have to do the math" beat.

Two specific elements amplified the move. First, the guide optics: the FY25 adjusted-EPS range looks cut on an operational basis even though the reported headline edged up — a nuance that does not survive a fast-money first read, and several wire reports framed it as a "reduced earnings forecast." Second, aesthetics: the full-year aesthetics guide was trimmed a third time, and while the YoY decline moderated, the trim was the headline the bears wanted. Neither is a fundamental deterioration — both are optics and positioning. The fade is the market efficiently re-pricing a good-but-already-discounted quarter, with the IPR&D headline supplying the excuse and the 21% run supplying the fuel.

Street Perspective

Debate: Is the IPR&D-Driven EPS "Collapse" a Real Problem or Pure Optics?

Bull view: The −38% adjusted-EPS decline is entirely a $1.50 IPR&D charge that AbbVie, uniquely, runs through its adjusted number. Strip it and the quarter earned ~$3.36, above guidance. The charge is the cost of building a de-risked 2030s pipeline out of cash flow — a feature of a value-creating BD machine, not a sign of operational weakness. Look through it and the beat-and-raise is clean.

Bear view: If IPR&D is a recurring, lumpy feature of every print — 30+ deals and counting — then it is not a "one-time" item investors get to ignore; it is a permanent tax on adjusted EPS that the company simply refuses to normalize. A "clean" guide that excludes future IPR&D will be cut all year by deals, so the headline always overstates what investors realize. The GAAP-to-adjusted gap ($0.10 vs. $1.86) is a real cash-vs-accounting divergence the market is right to discount.

Our take: The bull has the better of it on substance — the operating quarter beat, and running IPR&D through adjusted EPS is the more conservative convention. But the bear's practical point stands: the print is structurally noisy, management will not give a steady-state IPR&D figure, and a stock valued on adjusted EPS will periodically take optics-driven hits like this one. That is a reason the multiple should not expand, not a reason to sell the business.

Debate: Has Aesthetics Troughed, or Is "Less Bad" a Head-Fake?

Bull view: The decline moderated to −3.7% from −8.1%, filler sentiment is "stabilizing," consumer campaigns are showing "nice pickup," and TrenibotE arrives in 2026 to activate new consumers. This is the trough-forming pattern — the moment the consumer recovers, a market-leading, low-penetration, cash-pay category snaps back to a growth contributor AbbVie owns cheaply inside the conglomerate.

Bear view: Management cut the full-year aesthetics guide a third time, would not call a trough, and described conditions as "more protracted than we anticipated." A moderating decline is still a decline, and the "natural look" sentiment shift pressuring fillers may be structural. This is a discretionary consumer business mis-housed inside a pharma multiple, and it continues to cap the consolidated growth and the re-rating.

Our take: The trend is genuinely better — −3.7% beats −8.1% and the leading indicators have stopped deteriorating — but a third guide cut means we cannot yet call it a confirmed trough. We read it as "less bad, not yet good." It moves aesthetics from a clear drag toward a stabilizing line, supportive of the Hold; a confirmed trough (our explicit upgrade trigger) would require a guide that stops going down.

Debate: After a 21% Run, Is the 4.5% Pullback an Entry Point?

Bull view: A 4.5% sell-off on an optics-driven headline, in a business that just beat-and-raised and lifted the dividend, is exactly the kind of overreaction that creates an entry. At $218, with a ~3.2% yield and the long-term guide raise still ahead at Q4/JPM, the risk/reward has improved versus the $228 pre-print level — you are buying a high-single/low-double-digit compounder on a manufactured dip.

Bear view: The stock is still up ~21% off its August level and ~28% YTD, trading well above where the franchise's growth rate and the aesthetics/oncology soft spots justify. A 4.5% pullback off a 21% run barely dents the run-up; it is not a washed-out level, and the obvious re-rating catalyst is deliberately deferred. There is no margin of safety here.

Our take: The bear has the better of the near-term setup. A 4.5% dip after a 21% run does not restore a margin of safety — it returns the stock to roughly where it traded a few weeks ago, still near the top of its 52-week range. None of our upgrade triggers (low-$180s entry, confirmed aesthetics trough, formal long-term-guide raise) was hit; the stock ran up into the print, not down to our level. This is precisely the discipline our August initiation called for: we did not chase the full multiple, and the 21% run plus a 4.5% give-back is the round-trip that proves the point.

Model & Valuation Framework

Valuation framework: At the $218.04 reaction-day close, ABBV trades at approximately 17.9x the IPR&D-inclusive FY25 adjusted-EPS midpoint of $10.63 — but that multiple is distorted by the IPR&D charge in the denominator. On the cleaner ex-IPR&D FY25 figure of ~$12.1–$12.2, the stock trades at ~17.9–18.0x... the same, because both numerator and denominator scale together; the more useful frame is forward FY26. On ~$13.50–$14.00 of FY26 ex-IPR&D adjusted EPS, ABBV trades at roughly 15.6–16.1x — a premium to the diversified large-cap pharma peer group (low-teens) that reflects the superior growth profile and the de-risked LOE, and a touch richer than the ~14–14.5x forward we noted at the $189 Q2 level.

Fair-value anchor / 12-month framing: We anchor fair value at roughly 15–16x forward (FY26) ex-IPR&D adjusted EPS of ~$13.50–$14.00, yielding a base-case range of ~$205–$225 (mid ~$215) — essentially in line with the $218 reaction-day close, supplemented by a ~3.2% dividend yield. A bull case (aesthetics confirms a trough, the long-term Skyrizi/Rinvoq guide is formally raised at Q4/JPM, 17x forward) supports the high-$230s/low-$240s and a retest of the 52-week high. A bear case (aesthetics deteriorates again, a 2026 tariff or IRA print, multiple compresses to 13–14x) supports the mid-to-high-$180s. The resulting up/down from $218 is roughly symmetric — perhaps +8–12% to the bull, −12–15% to the bear — which, even with the dividend, does not clear the bar for Outperform versus the S&P 500. We nudge our fair-value anchor up modestly from the ~$205 Q2 midpoint to ~$215, reflecting the higher FY26 base and the moderating aesthetics decline — but the stock has run up to meet that higher anchor, so the rating math is unchanged. Hence Hold.

Thesis Scorecard Post-Earnings

We carry forward the bull and bear pillars established at our August (Q2) initiation and grade each against the Q3 evidence as of November 1, 2025.

Overall: The business thesis strengthened at the margin — Humira broke below $1B, aesthetics and oncology both improved their declines, and the platform delivered a third beat-and-raise — while the central bear pillar (full valuation) was confirmed emphatically by a 4.5% sell-off after a 21% run. The two bear pillars that defined the Q2 caution (aesthetics decline, oncology drag) are both moving in the right direction but neither has yet flipped to a positive. The net of a stronger business and a still-full price is, again, a balanced setup.

Action: Maintaining Hold. Our August initiation declined to chase a full multiple and flagged three upgrade triggers: a pullback toward the low-$180s, a confirmed aesthetics trough, or a formal long-term Skyrizi/Rinvoq guide raise. The stock ran 21% away from the first trigger; the second is improving but not confirmed (the FY aesthetics guide was cut again); the third was deferred to Q4/JPM for the second straight quarter. None was hit. We reiterate all three. We would upgrade to Outperform on a meaningful pullback that restores a margin of safety, on a guide that stops cutting aesthetics, or on the formal long-term-guide raise. We would move to Underperform only on a genuine operational crack (a re-acceleration of the aesthetics decline plus an adverse 2026 policy print) that the platform growth cannot earn through — not in evidence today.

Bottom Line: A Stronger Business, the Same Full Price

AbbVie's Q3 was, underneath the headline, a better quarter than Q2: revenue beat by ~$300M, the ex-Humira platform compounded above 20%, Humira finally fell below $1B and turned the five-year cliff into a footnote, neuroscience grew 20%, oncology stopped dragging, the aesthetics decline halved, the dividend rose 5.5%, and management beat-and-raised for the third straight quarter. The only genuinely bad number in the release — the −38% adjusted EPS — is an accounting artifact of a $1.50 IPR&D charge for building the 2030s pipeline; ex-IPR&D the quarter earned ~$3.36, above guidance.

And yet the stock fell 4.5%. That is the entire investment case in one data point. ABBV ran ~21% from its post-Q2 level to $228 into this print, and a good operating quarter with an ugly-optics headline was the cue for the market to take some of it back. Our August discipline — "a great business at a fair price; don't chase the multiple" — was validated, not refuted: we declined to pay up, the stock ran without us, and a 4.5% give-back after a 21% run leaves it roughly where it traded a few weeks ago, still near the top of its range, with the obvious re-rating catalyst once again deferred to December.

We maintain our Hold rating on AbbVie. The franchise is firing on all cylinders and getting better at the edges — this is a name we still want to own at the right price. But at $218, after a 21% run, with the aesthetics trough unconfirmed and the long-term guide raise still ahead, the forward 12-month risk/reward versus the S&P 500 remains balanced. We reiterate our three upgrade triggers and stay disciplined.